The Fund Grade · free · no account needed
What grade does VGHCX get?
Morningstar rates funds on what they returned. We grade them on where their money sits today: how much of the book overlaps with the converged buys of the top specialist stock pickers.
Fundprints Fund Grade · as of 2026-10-01
Vanguard Health Care Fund Investor Shares
#170 of 500 graded active funds · blend · large segment peer group
The point · specialist footprint
VGHCX puts more of its book behind proven specialists than 75% of graded funds.
Bottom 20%
Bottom 40%
Middle
● Top 40%
Top 20%
That has mattered: over the past 2.7 years, funds on this rung beat bottom-rung funds by about 3.8% per quarter, and beat the S&P in 43% of fund-quarters versus their 22%. The evidence argues this fund earns its seat.
10,000+ funds tracked · the graded specialists among them drive every read
You pay 0.33% a year for a B.
The grade scores this fund's specialist share, the slice that overlaps what the top 1% of proven funds are building. We ignore index ballast and names outside our edge on purpose: that slice is small, and it's what decides the outcome.
VGHCX vs the Honor Roll · share card ↗Conviction exposure
41.1%
of the book in specialist-converged names
Late-stage weight
24.3%
of the book in Crowded or Fading names
Active share
96.8%
how far it strays from the index
The best grades have beaten the worst by about +5% a year since we began grading. The gap held in 9 out of 10 months. Measured on filings as they were published, no hindsight.
Inside the book: top names by stage · as of 2026-10-20
We email you the day it crosses 50% crowded, and where you stand every month.
Graded monthly from point-in-time filings. A description of where the money sits, not a recommendation. Evidence, not advice.
The read · what to do with it
VGHCX earns a B grade with 41% specialist backing and a low 0.33% fee, making it a reasonably priced health care option. Specialists are building early positions in MRK and JNJ, which is the most encouraging signal here. The concern is a cluster of fading names, EW, ISRG, CVS, and ALNY, that together represent real weight in the portfolio.
→ Watch EW, ISRG, CVS, and ALNY closely since specialists are actively leaving all four positions.
→ Compare the Early Conviction weight in MRK and JNJ against the 24.3% late stage drag before adding more shares.
Support leaving these positions
Read from today's disclosed book. Evidence, not advice.